Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

Participants needed: 741
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: NovoCure GmbHUpdated: Aug 19, 2026Locations: 102
Eligibility criteria

The participant (or legally acceptable representative) has provided documented i... [+7]

Has received prior therapy with an anti-Programmed Cell Death 1 (PD-1), anti- Pr... [+8]

Read more
Status: Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Participants needed: 734
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: NovoCure GmbHUpdated: Jun 25, 2026Locations: 98
Eligibility criteria

≥22 years of age in the USA [+8]

Mixed small cell and NSCLC histology. [+17]

Read more